GSK (GSK) is in advanced discussions to purchase privately-owned U.S. biotech IDRx, which is working on a treatment for rare gastrointestinal tumors, the Financial Times’ Oliver Barnes and Hannah Kuchler report, citing people close to the talks. IDRx, whose backers include Andreessen Horowitz, RA Capital and Blackstone (BX), was last valued at $430M at a funding round in August, could be sold for up to $1B.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GSK:
- GSK, Pfizer RSV vaccines to carry warnings of GBS, Reuters reports
- Bird flu vaccine maker Moderna shares jump after first US death, Barron’s says
- GSK’s Cancer Drug Receives FDA Breakthrough Designation
- GSK’s GSK’227 receives FDA BTD for treating adults with relapsed osteosarcoma
- GSK’s Nucala Gains Approval in China for CRSwNP
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
